Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines (2021)

Peer-Reviewed Study · Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC · July 2021

Bryant A et al., 2021-07: Systematic review and meta-analysis of 24 randomized trials (3406 participants) concluding that ivermectin reduced COVID-19 deaths by about 62% and cut infection in prophylaxis trials by 86%, with GRADE certainty rated moderate and low respectively.

Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence).

Bryant A et al., 2021-07: Systematic review and meta-analysis of 24 randomized trials (3406 participants) concluding that ivermectin reduced COVID-19 deaths by about 62% and cut infection in prophylaxis trials by 86%, with GRADE certainty rated moderate and low respectively. Systematic review, meta-analysis and trial sequential analysis; 24 RCTs, 3406 participants; searches to 25 April 2021. Mortality meta-analysis of 15 trials, n=2438, RR 0.38 (0.19-0.73), I2 49%, rated moderate certainty; prophylaxis 86% reduction (79-91%), low certainty. Authors declare: 'The authors have no conflicts of interest to declare.' No drug-maker funding declared. This review's inclusion of the subsequently withdrawn Elgazzar preprint and other high-risk-of-bias trials is the central published criticism of it (see IVE-44 to IVE-46); the paper itself was not retracted. Recorded as published. Study type: review.